Clinical Trial Update: Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing radium-223 dichloride to placebo with hormonal therapy in bone-predominant HER2-negative, hormone receptor-positive metastatic breast ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Breast Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2020-08-10